Drug-Drug Interactions between Rosuvastatin and Oral Antidiabetic Drugs Occurring at the Level of OATP1B1

2012 ◽  
Vol 41 (3) ◽  
pp. 592-601 ◽  
Author(s):  
E. van de Steeg ◽  
R. Greupink ◽  
M. Schreurs ◽  
I.H.G. Nooijen ◽  
K.C.M. Verhoeckx ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Antidiabetic Drugs ◽  
Oral Antidiabetic Drugs ◽  
Oral Antidiabetic

Drug interactions in diabetics

1979 ◽  
Vol 17 (10) ◽  
pp. 37-40
Keyword(s):  
Blood Glucose ◽  
Drug Interactions ◽  
Antidiabetic Drugs ◽  
Diabetic Patients ◽  
Oral Antidiabetic Drugs ◽  
Hypoglycaemic Agents ◽  
Oral Antidiabetic

Drugs taken by diabetic patients for reasons other than the control of blood glucose may affect the response to insulin or oral antidiabetic drugs. Drugs may also interfere with tests for glucose or ketones in the urine or those estimating glucose in the blood. In Britain about a quarter of a million people take hypoglycaemic agents and many others are treated by diet alone, so it is clearly important to be aware of these special problems.

scholarly journals A STUDY OF THE POSSIBLE DRUG-DRUG INTERACTIONS INVOLVING ORAL ANTIDIABETIC DRUGS IN PATIENTS WITH TYPE II DIABETES

2019 ◽  
Vol 10 (5) ◽  
pp. 141-144
Author(s):  
Sapna K Dongre ◽  
Anju Paulose ◽  
Nagesh G N ◽  
Amrutha Jacob ◽  
Suhag As-Hal ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Type Ii Diabetes ◽  
Antidiabetic Drugs ◽  
Type Ii ◽  
Oral Antidiabetic Drugs ◽  
Oral Antidiabetic

scholarly journals Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs

Pharmaceutics ◽  
2011 ◽  
Vol 3 (4) ◽  
pp. 680-705 ◽  
Author(s):  
Sabine Klatt ◽  
Martin F. Fromm ◽  
Jörg König
Keyword(s):  
Drug Interactions ◽  
Antidiabetic Drugs ◽  
Oral Antidiabetic Drugs ◽  
Oral Antidiabetic

scholarly journals Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males

2015 ◽  
Vol 32 (5) ◽  
pp. 404-417 ◽  
Author(s):  
Takashi Sasaki ◽  
Yutaka Seino ◽  
Atsushi Fukatsu ◽  
Michito Ubukata ◽  
Soichi Sakai ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Antidiabetic Drugs ◽  
Oral Antidiabetic Drugs ◽  
Oral Antidiabetic

scholarly journals Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study

Pituitary ◽  
2021 ◽  
Author(s):  
Susan L. Samson ◽  
Feng Gu ◽  
Ulla Feldt-Rasmussen ◽  
Shaoling Zhang ◽  
Yerong Yu ◽  
...  
Keyword(s):  
Cushing’S Disease ◽  
Rescue Therapy ◽  
Antidiabetic Drugs ◽  
Cushing's Disease ◽  
Oral Antidiabetic Drugs ◽  
Open Label ◽  
Oral Antidiabetic ◽  
Open Label Phase ◽  
Core Phase ◽  
Phase Iv

Abstract Purpose Pasireotide is an effective treatment for acromegaly and Cushing’s disease, although treatment-emergent hyperglycemia can occur. The objective of this study was to assess incretin-based therapy versus insulin for managing pasireotide-associated hyperglycemia uncontrolled by metformin/other permitted oral antidiabetic drugs. Methods Multicenter, randomized, open-label, Phase IV study comprising a core phase (≤ 16-week pre-randomization period followed by 16-week randomized treatment period) and optional extension (ClinicalTrials.gov ID: NCT02060383). Adults with acromegaly (n = 190) or Cushing’s disease (n = 59) received long-acting (starting 40 mg IM/28 days) or subcutaneous pasireotide (starting 600 µg bid), respectively. Patients with increased fasting plasma glucose (≥ 126 mg/dL on three consecutive days) during the 16-week pre-randomization period despite metformin/other oral antidiabetic drugs were randomized 1:1 to open-label incretin-based therapy (sitagliptin followed by liraglutide) or insulin for another 16 weeks. The primary objective was to evaluate the difference in mean change in HbA1c from randomization to end of core phase between incretin-based therapy and insulin treatment arms. Results Eighty-one (32.5%) patients were randomized to incretin-based therapy (n = 38 received sitagliptin, n = 28 subsequently switched to liraglutide; n = 12 received insulin as rescue therapy) or insulin (n = 43). Adjusted mean change in HbA1c between treatment arms was – 0.28% (95% CI – 0.63, 0.08) in favor of incretin-based therapy. The most common AE other than hyperglycemia was diarrhea (incretin-based therapy, 28.9%; insulin, 30.2%). Forty-six (18.5%) patients were managed on metformin (n = 43)/other OAD (n = 3), 103 (41.4%) patients did not require any oral antidiabetic drugs and 19 patients (7.6%) were receiving insulin at baseline and were not randomized. Conclusion Many patients receiving pasireotide do not develop hyperglycemia requiring oral antidiabetic drugs. Metformin is an effective initial treatment, followed by incretin-based therapy if needed. ClinicalTrials.gov ID: NCT02060383.

Sign in / Sign up

Export Citation Format

Share Document